AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)


  • A proven track record of putting shareholders first is part of the litmus test that I use before buying stocks.
  • AbbVie’s recent 4.7% dividend hike builds on an impressive dividend growth streak that it inherited from its former parent company, Abbott Labs.
  • The pharmaceutical titan held up well in the third quarter, posting a double beat.
  • AbbVie appears to be trading at a 9% discount to fair value.
  • The ultra SWAN looks positioned to outperform the S&P 500 by a wide margin through the coming 10 years.

1 2 5 10 100 Different dollar bills in a pile as background

U.S. banknotes in the background.

alfexe/iStock via Getty Images

As a dividend growth investor, I don’t put my hard-earned money into just any old business that pays a dividend. What has become more true with each passing year is that my

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV, ABT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *